Ligand Pharmaceuticals

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$51,812
$41,531
$30,978
$28,101
Gross Profit
39,317
30,368
19,910
26,437
EBITDA
3,143
-54,765
12,231
26,658
EBIT
-5,851
-64,122
2,988
17,228
Net Income
-7,172
-51,911
86,139
18,188
Net Change In Cash
51,812
41,531
30,978
28,101
Free Cash Flow
22,289
11,118
18,586
-42,680
Cash
63,619
18,139
50,093
22,954
Basic Shares
18,419
18,028
18,122
17,676

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$131,314
$196,245
$277,133
$186,419
Gross Profit
96,265
143,418
214,957
156,000
EBITDA
101,727
54,407
133,161
69,052
EBIT
64,316
11,013
91,824
41,086
Net Income
52,154
-5,219
57,138
-2,985
Net Change In Cash
131,314
196,245
277,133
186,419
Cost of Revenue
-28,440
-24,311
Free Cash Flow
-4,272
119,927
70,037
50,128
Cash
22,954
45
19,522
47,619
Basic Shares
17,757
16,868
17,246
16,184

Earnings Calls

Quarter EPS
2024-09-30
$1.84
2024-06-30
$1.40
2024-03-31
$1.20
2023-12-31
$1.38